BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Nevro Corp Nabs $58 Million for Anti-Pain Device


7/19/2011 10:50:00 AM

MENLO PARK, Calif.--(BUSINESS WIRE)--Nevro Corp., a neuromodulation company focused on relief of chronic pain, announced today that it has completed a $58 million financing round led by new investor, Johnson & Johnson Development Corporation (JJDC). Existing investors participating in this financing round included Aberdare Ventures, Accuitive Medical Ventures, Bay City Capital, Mayo Clinic, MPM Capital, and Three Arch Partners.

The funds will be used to sponsor a pivotal clinical study in the U.S. and provide continued support for the company’s international commercialization strategy.

“We are excited to add JJDC to our experienced team of investors,” said Michael DeMane, chief executive officer of Nevro Corp. “This round of financing will underpin our expansion in global markets and fund U.S. clinical development efforts for this next generation neuromodulation technology. There is a significant need for better outcomes, a simpler procedure, and an enhanced patient experience in the treatment for chronic pain. We hope to address these needs.”

About Nevro Corp

Nevro Corp., headquartered in Menlo Park, California, is a privately-held medical device company founded in 2007 to provide advances in chronic pain relief through neuromodulation technology. The Nevro Spinal Cord Stimulation System received CE mark in 2010 and is now commercially available at leading centers outside the United States. For more information, please visit www.nevro.com. nt for chronic pain. We hope to address these needs.”


Read at BioSpace.com
Read at Xconomy
Read at MassDevice
Read at Pharmiweb

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES